Log In
BCIQ
Print this Print this
 

Intranasal Ampligen

  Manage Alerts
Collapse Summary General Information
Company Hemispherx Biopharma Inc.
DescriptionIntranasal formulation of the double-stranded RNA antiviral agent that agonizes toll-like receptor 3 (TLR3) used in conjunction of a commercially approved seasonal influenza vaccine
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid
Latest Stage of DevelopmentIND
Standard IndicationInfluenza virus
Indication DetailsVaccinate against influenza virus
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today